CompletedNCT00545168Updated Oct 11, 2012Results posted

Safety and Efficacy Study of NatrOVA Creme Rinse - 1% and NIX Creme Rinse in Subjects 6 Months or Older With Head Lice

A Phase 3 interventional study of Spinosad and Spinosad in Pediculus Capitis Infestation, sponsored by ParaPRO LLC. Completed at 6 sites in United States. Open to participants aged 6 Months and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2012-10-11.

Sponsored by ParaPRO LLC · Phase 3, Interventional, and Treatment

Phase: Phase 3
Study type: Interventional
Enrollment: 480
Allocation: Randomized
Ages: 6 Months and older
Sex: All

Study summary

A comparative safety and efficacy study of NatrOVA Creme Rinse - 1% versus NIX Creme Rinse, under actual use conditions in subjects 6 months of age or greater who are infested with Pediculosis capitis (Head lice).

Read the detailed description

This is a Phase 3 multi-site, randomized, evaluator/investigator-blinded, three-arm, parallel group study evaluating the safety and efficacy of NatrOVA Creme Rinse - 1% (with nit combing and without nit combing) versus NIX Creme Rinse in an "actual use" environment.

Conditions studied

Pediculus Capitis Infestation

Browse trials for

Parasitic Diseases 61

Keywords

head lice

Who can participate

Ages eligible: 6 Months and older
Sexes eligible: All
Accepts healthy volunteers: Yes

Inclusion criteria

Subjects must have an active head lice infestation present at Day 0.
Subjects can be female or male, at least 6 months of age.
Subjects must be in good general health based on medical history.
Each subject must have an appropriately signed Informed Consent agreement. Subjects under the age of 12 must also provide written or oral assent.
The subject/caregiver must be able to read English or Spanish at a 7th grade level.
The parent or guardian within a household must be willing to allow other household members to be screened for head lice. If other household members are found to have a head lice infestation, they should also be enrolled in the study.
Subjects must agree to not use any other form of lice treatment during the course of the study and must agree not to use any of the excluded concomitant medications.
Subjects must agree not to cut or chemically treat their hair in the period between the initial treatment and the final visit.
Subjects/caregiver must demonstrate a clear understanding of his/her requirements for study participation and agree to comply with study instructions.

Exclusion criteria

Exclusion Criteria:

Individuals with history of irritation or sensitivity to pediculicides or hair care products.
Individuals with any visible skin/scalp condition at the treatment site which, in the opinion of the investigative personnel or Sponsor, will interfere with the evaluation.
Individuals who require treatment with topical salicylic acid, topical corticosteroids, anthralin, vitamin D analogs, retinoids, immunosuppressants, topical hair growth formulations, and topical dandruff treatments.
Infested subjects who have been previously treated with a pediculicide within the 48 hours prior to the study.
Individuals with a condition or illness that, in the opinion of the Investigator, may compromise the objective of the protocol.
Individuals receiving systemic or topical drugs or medications, including systemic antibiotics, which in the opinion of the investigative personnel or study monitor may interfere with the study results.
Individuals who have participated in a clinical trial within the past 30 days.
Individuals (or individuals from households) who, in the opinion of the Investigator, do not understand the requirements for study participation and/or may be likely to exhibit poor compliance.
Individuals with household members who are infested with lice but are unwilling or unable to enroll in the study or to use the standard course of lice treatment.
Females who are pregnant or nursing. Females of childbearing potential must have a negative urine pregnancy test prior to treatment at Day 0. If a household has a pregnant female with an active case of head lice, the entire household is excluded from participation. If the pregnant household member does not have lice, this individual must NOT be the caregiver (one who provides treatment to other household members).
Sexually active females not using effective contraception.
Individuals who have a history of drug abuse in the past year.

Study design

Phase: Phase 3
Primary purpose: Treatment
Allocation: Randomized
Intervention model: Parallel assignment
Masking: Double (Investigator, Outcomes assessor)
Enrollment: 480 participants (actual)

Study arms

Experimental
A - NatrOVA 1% - no nit combing
NatrOVA Creme Rinse (spinosad) 1% - no nit combing required
Drug: Spinosad
Experimental
B - NatrOVA 1% - nit combing required
NatrOVA Creme Rinse (spinosad) 1% - nit combing regimen required
Drug: Spinosad
Active comparator
C - NIX
Nix Creme Rinse (permethrin 1%) applied according to OTC Instructions for Use
Drug: Permethrin 1%

Interventions

DrugSpinosad
10 minute topical application of product, followed by a complete rinse off.
Also known as: Natroba (spinosad) Topical Suspension, 0.9%
DrugSpinosad
10 minute topical application followed by a complete rinse off, followed by a nit combing regimen.
Also known as: Natroba (spinosad) Topical Suspension, 0.9%
DrugPermethrin 1%
Topical application for 10 minutes, followed by a complete rinse off, followed by a nit combing regimen
Also known as: NIX Creme Rinse

What researchers measure

Primary outcomes

Efficacy of NatrOVA Creme Rinse - 1% Relative to NIX Creme Rinse in Subjects Infested With Head Lice
The primary efficacy endpoint was the proportion of primary subjects in the enrolled households who were lice free (no live lice, adults or nymphs), as assessed by the trained evaluator, 14 days after the last treatment (i.e., Day 14 for subjects who treated once and Day 21 for subjects who treated twice).
Time frame: Assessment were made 14 days following the final product treatment

Secondary outcomes

Evaluation of the Safety of NatrOVA Creme Rinse - 1% Based Upon Reported Adverse Events and Observed Skin/Scalp Reactions.
To evaluate the safety of NatrOVA® 1% Creme Rinse based upon reported adverse events and observed skin/scalp reactions. Additional safety assessments included cutaneous/ocular irritation.
Time frame: Participants were followed for a minimum of 14 days (1 treatment) and a maximum of 21 days (2 treatments)

Results

Posted Oct 11, 2012

Participant flow

The first subject signed an informed consent and enrolled into the study on 21 September 2007; the last follow up visit occurred on 8 April 2008.

Participant flow — Overall Study
Milestone	A - NatrOVA 1% - no Nit Combing	B - NatrOVA 1% - Nit Combing Required	C - NIX
Started	203	63	214
Completed	187	58	193
Not completed	16	5	21
Withdrew: Lost to follow-up	5	5	5
Withdrew: Withdrawal by subject	9	0	13
Withdrew: Protocol violation	1	0	1
Withdrew: Visit for day 21 was not done in error	1	0	2

Outcome measures

SecondaryEvaluation of the Safety of NatrOVA Creme Rinse - 1% Based Upon Reported Adverse Events and Observed Skin/Scalp Reactions.

To evaluate the safety of NatrOVA® 1% Creme Rinse based upon reported adverse events and observed skin/scalp reactions. Additional safety assessments included cutaneous/ocular irritation.

Time frame:: Participants were followed for a minimum of 14 days (1 treatment) and a maximum of 21 days (2 treatments)
Reported as:: Number · Incidents

Evaluation of the Safety of NatrOVA Creme Rinse - 1% Based Upon Reported Adverse Events and Observed Skin/Scalp Reactions.
Incidents	A/B - NatrOVA 1% - With/Without Nit Combing	C - NIX
Ear and labyrinth disorders - Ear pain	1	0
Eye disorders - Eye irritation	0	1
Gastrointestinal disorders - Diarrhea	0	2
Gastroesophageal reflux disease	1	0
Gastrointestinal disorders - Nausea	0	1
Administration site conditions - Erythema	2	14
Administration site conditions - Exfoliation	1	0
Administration site conditions - Irritation	0	1
Infections and infestations - Ear infection	0	1
Infections and infestations -Gastroenteritis viral	0	1
Infections and infestations - Nasopharyngitis	1	0
Infections - Upper respiratory tract infection	1	1
Musculoskeletal disorder - Fibromyalgia	0	1
Nervous system disorders - Dizziness	1	0
Pregnancy	0	1
Respiratory -Chronic obstructive pulmonary disease	0	1

PrimaryEfficacy of NatrOVA Creme Rinse - 1% Relative to NIX Creme Rinse in Subjects Infested With Head Lice

The primary efficacy endpoint was the proportion of primary subjects in the enrolled households who were lice free (no live lice, adults or nymphs), as assessed by the trained evaluator, 14 days after the last treatment (i.e., Day 14 for subjects who treated once and Day 21 for subjects who treated twice).

Time frame:: Assessment were made 14 days following the final product treatment
Reported as:: Number · participants

Efficacy of NatrOVA Creme Rinse - 1% Relative to NIX Creme Rinse in Subjects Infested With Head Lice
participants	A - NatrOVA 1% - no Nit Combing	B - NatrOVA 1% - Nit Combing Required	C - NIX
Success (no live lice present)	72	17	36
Failure (live lice present)	11	4	48

Adverse events

Collected over Through out the study (7 months).. Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
Group	Deaths	Serious	Other
A/B - NatrOVA 1% - With/Without Nit Combing	—	0/258 (0%)	2/258 (0.8%)
C - NIX	—	1/211 (0.5%)	16/211 (7.6%)

Most frequent serious events

Most frequent serious events
Event	A/B - NatrOVA 1% - With/Without Nit Combing	C - NIX
Gastrointestinal ViralGastrointestinal disorders	0/258	1/211

Most frequent other events

Most frequent other events
Event	A/B - NatrOVA 1% - With/Without Nit Combing	C - NIX
Application site erythemaGeneral disorders	2/258	14/211
DiarrheaGastrointestinal disorders	0/258	2/211

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)	A - NatrOVA 1% - no Nit Combing	B - NatrOVA 1% - Nit Combing Required	C - NIX	Total
<=18 years	147	46	147	340
Between 18 and 65 years	56	17	64	137
>=65 years	0	0	3	3

Age Continuous
Age Continuous(years)	A - NatrOVA 1% - no Nit Combing	B - NatrOVA 1% - Nit Combing Required	C - NIX	Total
Mean	15 ± 14	14 ± 13	16 ± 15	16 ± 14

Sex: Female, Male
Sex: Female, Male(Participants)	A - NatrOVA 1% - no Nit Combing	B - NatrOVA 1% - Nit Combing Required	C - NIX	Total
Female	166	48	185	399
Male	37	15	29	81

Region of Enrollment
Region of Enrollment(participants)	A - NatrOVA 1% - no Nit Combing	B - NatrOVA 1% - Nit Combing Required	C - NIX	Total
United States	203	63	214	480

Study locations

6 sites

Advanced Dermatology and Cosmetic Surgery
Ormond Beach, Florida 32174, United States
Lice Solutions Network, Inc.
West Palm Beach, Florida 33407, United States
Concentrics Center for Research
Indianapolis, Indiana 46240, United States
Alegent Health Clinic
Council Bluffs, Iowa 51503, United States
Celia Reyes-Acuna
Corpus Christi, Texas 78411, United States
Wee Care Pediatrics
Layton, Utah 84041, United States

Registry details

Key details

Study ID: NCT00545168
Lead sponsor: ParaPRO LLC
Responsible party: Sponsor
First posted: Oct 17, 2007
Start date: Sep 2007
Primary completion: Mar 2008
Completion: May 2008
Results posted: Oct 11, 2012
Last update: Oct 11, 2012

Study contacts

Bill Miller, MD

study director · Concentrics Research

Oversight

Data monitoring committee: No

View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Parasitic Diseases→

Other studies from this sponsor

ParaPRO LLC

Start the discussion